文献速递胃肠外科

内镜切除与胃切除术治疗cT1a胃腺癌:淋巴结升期的预测因素

Endoscopic resection versus gastrectomy for clinical T1a gastric adenocarcinoma: Predictors of nodal upstaging.
PubMed 文献 · Surgery · 2025-05-07

基于美国国家癌症数据库2010至2021年2177例cT1aN0M0胃腺癌患者的回顾性分析,比较内镜切除与胃切除术。内镜切除组切缘阳性率更高(15.3% vs 4.6%),但两组生存相似(log-rank P = .24)。胃切除术组病理淋巴结升期率为15.6%,肿瘤大小、低分化、脉管侵犯和切缘阳性是淋巴结升期的预测因素。

要点

  • cT1aN0M0胃腺癌内镜切除与胃切除术生存相似。
  • 胃切除术组约15.6%出现病理淋巴结升期。
  • 脉管侵犯是淋巴结升期最强预测因素(OR 13.15)。

核心结论

  • 内镜切除治疗cT1aN0M0早期胃腺癌可获得与胃切除术相似的生存。
  • 约15%的胃切除术患者出现病理淋巴结升期,肿瘤大小、分化程度、切缘阳性和脉管侵犯是重要预测因素。

研究设计与样本

  • 回顾性分析美国国家癌症数据库2010至2021年cT1aN0M0胃腺癌患者,比较内镜切除与胃切除术,主要结局为总生存和淋巴结升期。

主要发现

  • 共纳入2177例患者,内镜切除1007例(46.3%),胃切除术1170例(53.7%)。
  • 内镜切除组切缘阳性率高于胃切除术组(15.3% vs 4.6%,P < .01)。
  • 两组生存相似(log-rank P = .24)。
  • 胃切除术组病理淋巴结升期率为15.6%。

关键数值与推荐

  • 淋巴结升期预测因素:肿瘤较大(OR 1.01,95%CI 1.01-1.02)、低分化(OR 2.65,95%CI 1.15-6.09)、脉管侵犯(OR 13.15,95%CI 7.86-22.01)、切缘阳性(OR 5.85,95%CI 2.30-14.87)。
  • 印戒细胞形态不预测淋巴结升期,但预测上述高危特征(OR 12.02,95%CI 4.60-31.39)。

临床怎么用

  • 对于cT1aN0M0胃腺癌,内镜切除可作为治疗选择,但需评估淋巴结升期风险。
  • 肿瘤大小、分化程度、切缘阳性和脉管侵犯应纳入治疗决策,尤其脉管侵犯提示高淋巴结升期风险。

局限性

  • 回顾性研究设计。
  • 基于数据库的回顾性分析可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic resection is increasingly favored as a first-line curative treatment over surgery for early gastric cancer with minimal risk of lymph node metastasis. Our objective is to identify factors that may guide the treatment decision between endoscopic resection and gastrectomy in early gastric cancer. METHODS: A retrospective analysis of the National Cancer Database from 2010 to 2021 for patients with cT1aN0M0 gastric adenocarcinoma was performed comparing endoscopic resection versus gastrectomy. Our main outcomes of interest were overall survival and lymph node upstaging. Multivariate logistic regression and Cox proportional hazards models were used. RESULTS: A total of 2,177 patients were identified; 1,007 (46.3%) had endoscopic resection and 1,170 (53.7%) had gastrectomy. On average, endoscopic resection patients were more likely to be male (72.6% vs 61.1%, P < .01), older (69.7 ± 10.9 vs 65.4 ± 13.1 years, P < .01), and non-Hispanic White (80.3% vs 67%, P < .01). Compared with gastrectomy, tumors undergoing endoscopic resection were smaller, lower grade, more often in the cardia, and had lower rates of lymphovascular invasion and signet morphology. Endoscopic resection resulted in higher margin positivity (15.3% vs 4.6%, P < .01), but both approaches had similar survival (log-rank P = .24). There was a pathologic lymph node upstaging rate of 15.6% in gastrectomy. Factors predicting lymph node upstaging included larger tumor size (odds ratio: 1.01, 95% confidence interval: 1.01-1.02), poor differentiation (odds ratio: 2.65, 95% confidence interval: 1.15-6.09), lymphovascular invasion (odds ratio: 13.15, 95% confidence interval: 7.86-22.01), and positive margins (odds ratio: 5.85, 95% confidence interval: 2.30-14.87). Although signet morphology did not predict lymph node upstaging, it predicted having those aforementioned high-risk features for lymph node upstaging (odds ratio: 12.02, 95% confidence interval: 4.60-31.39). CONCLUSION: In the real-world analysis of early gastric cancer treatment, endoscopic resection alone achieved similar survival to gastrectomy for cT1aN0M0 early gastric cancer. Despite these early gastric cancer staged as cN0, approximately 15% of gastrectomy patients had lymph node upstaging. We found tumor size, grade, margin positivity, and particularly lymphovascular invasion to be important clinical predictors of pathologic lymph node upstaging that should be considered in early gastric cancer treatment decision-making.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Salehi O, Somasundar P, Espat NJ, et al. Endoscopic resection versus gastrectomy for clinical T1a gastric adenocarcinoma: Predictors of nodal upstaging. Surgery. 2025. PMID: 40340160. doi:10.1016/j.surg.2025.109377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。